Monthly Archives: September 2011

Europe threatens to break off India free-trade talks

EU officials warn that negotiations will be broken off if an agreement is not reached by February 2012 AFP , Tuesday 27 Sep 2011 European governments are threatening to break off negotiations with India on a free-trade deal the EU … Continue reading

Posted in EU-India FTA, IP Rights | Leave a comment

Novartis: Making a killing in Profits

Posted in patent evergreening, Sec 3 (d) | Leave a comment

Press Release: Novartis attempts to weaken Indian Patent Law that threatens to restrict access to live-saving medicines for millions in the developing world

Act Up -Paris Press Release This afternoon, Act Up-Paris protested in front of Novartis-France headquarters in Rueil Malmaison, a town near Paris. The activists blocked the entrance of the building and shut the gate. They unfurled a banner which said … Continue reading

Posted in patent evergreening, Sec 3 (d), TRIPS plus | Tagged , , | Leave a comment

Generic Prescription Drugs saved $931 billion in United States in past 10 years, says US generic industry

Press Release by GPhA, 21 Sep 2011 New Study Finds Use of Generic Prescription Drugs Saved Consumers and the U.S. Health Care System $931 Billion Over Past 10 Years Savings Reached $158 Billion in 2010, Averaging $3 Billion Weekly WASHINGTON, … Continue reading

Posted in Drug Pricing, Generic drug, IP Rights | Tagged , , | Leave a comment

Natco Pharma’s compulsory license application for Cancer Drug- Sorafenib Tosylate

Recently, Natco Pharma, an Indian generic company had applied for Compulsory License (CL) to produce and sell the generic verson of Bayer’s patented cancer drug Sorafenib Tosylate (Brand name-Nexavar).This drug is used in the treatment for liver and kidney cancer. … Continue reading

Posted in Compulsory Licensing, Indian Patent Law, TRIPS flexibilities | Tagged , , , , , | 2 Comments

Slideshow on Pharmacy to the Developing World May Shut Shop: IBSA News

IBSA News, Sep 19 2011 India’s generic drugs are a lifeline not only for millions of poor people in India, but also to developing countries in Africa, Asia and Latin America. So much so that India is known as the … Continue reading

Posted in EU-India FTA, Generic drug, HIV/Aids, TRIPS | Tagged , | Leave a comment

Comparative Analysis of the United States’ TPPA Intellectual Property Proposal and Malaysian Law

Public Citizen has done a comparative analysis of leaked Intellectual Property Chapter of US Trans-Pacific Partnership Agreement proposal with the Malaysian patent law to show the dangers of this agreement on access to medicines. The next round of TPP negotiations … Continue reading

Posted in TPPA, Trans-Pacific Partnership Agreement | Leave a comment

USTR IPR Text Moves Away From ‘May 10′ Deal, Draws Fire From NGOs

Inside U.S. Trade – 09/16/2011 Posted: September 15, 2011 The U.S. proposal on pharmaceutical patent provisions in the Trans-Pacific Partnership (TPP), tabled this week during the eighth round of talks, moves away from patent provisions contained in the “May 10″ … Continue reading

Posted in data exclusivity, Generic drug, Patent Term Extension, Pharmaceutical Benefits Scheme, Trans-Pacific Partnership Agreement | Tagged | Leave a comment

Sharma writes to PM on pharma M&A concerns

Minister seeks ‘procedural filter’ on investments by foreign companies in Indian pharmaceutical firms Asit Ranjan Mishra The Livemint, 21 September 2011 India’s commerce and industry ministry is getting serious with its effort to have all foreign investment in Indian pharmaceutical … Continue reading

Posted in FDI, Mergers and Acquisitions | Tagged , , | Leave a comment

Briefing Paper on EU-Andean FTA negotiations

The bilateral trade agreement negotiations between the EU and Peru & Colombia have concluded and implementation is now pending. Health Action International (HAI) Europe, has prepared a briefing paper providing an overview of the agreements’ history: the initial European demands on Intellectual Property; … Continue reading

Posted in data exclusivity, Drug Pricing, EU-Andean FTA, IPR Enforcement, Patent Term Extension, TRIPS plus | Leave a comment